Effexor, a serotonin norepinephrine reuptake inhibitor (SNRI), is associated with potential risks during pregnancy, including severe birth defects like lethal cardiac anomalies in newborns exposed to the drug in late pregnancy. The document discusses a lawsuit filed by a couple whose baby died shortly after birth, allegedly due to mother’s use of Effexor, highlighting the importance of informing patients, especially pregnant women, about the risks associated with antidepressants. It emphasizes that the FDA has classified Effexor as category C, indicating potential fetal risks without adequate human studies, and advises caution in prescribing this medication to pregnant women.